论文部分内容阅读
PILLAR-2:A randomized,double-blind,placebo-controlled,phase Ⅲ study of adjuvant everolimus(EVE)in pa
【作 者】
:
【机 构】
:
Mayo Clinic,Rochester,MN National Cancer Center H
【出 处】
:
2016年临床肿瘤学新进展学术研讨会
【发表日期】
:
2016年5期
其他文献
OV21/PETROC:A randomized Gynecologic Cancer Intergroup(GCIG)phase Ⅱ study of intraperitoneal(IP)vers
会议
Baseline quality of life(QOL)as a predictor of stopping chemotherapy early,and of overall survival,i
会议
Crenolanib besylate,a type Ⅰ pan-FLT3 inhibitor,to demonstrate clinical activity in multiply relapse
会议
Final results of a phase Ⅲ randomized trial of CPX-351 versus 7+3 in older patients with newly diagn
会议
Phase Ⅲ non-inferiority study of cabazitaxel(C)20 mg/m2(C20)versus 25 mg/m2(C25)in patients(pts)with
会议
会议
A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage nonbulky Hodg
会议
Treatment-free remission(TFR)in patients(pts)with chronic myeloid leukemia in chronicphase(CML-CP)tr
会议